Palatin Technologies, Inc. (PTN)

NYSEAMERICAN: PTN · IEX Real-Time Price · USD
3.36
+0.02 (0.60%)
At close: Dec 9, 2022 3:59 PM
3.39
+0.03 (0.89%)
After-hours: Dec 9, 2022 6:30 PM EST
0.6%
Market Cap 34.58M
Revenue (ttm) 2.18M
Net Income (ttm) -37.34M
Shares Out 9.63M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Aug 31, 2022
Volume 15,216
Open 3.3
Previous Close 3.34
Day's Range 3.17 - 3.51
52-Week Range 3.09 - 15
Beta 0.72
Analysts Buy
Price Target 43.86 (+1,205.4%)
Earnings Date Nov 14, 2022

About PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a p... [Read more]

Industry Biotechnology
IPO Date Oct 28, 1993
CEO Carl Spana
Employees 33
Stock Exchange NYSEAMERICAN
Ticker Symbol PTN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PTN stock is "Buy." The 12-month stock price forecast is 43.86, which is an increase of 1,205.36% from the latest price.

Price Target
$43.86
(1,205.36% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

3 weeks ago - Zacks Investment Research

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar...

3 weeks ago - PRNewsWire

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the o...

1 month ago - PRNewsWire

Palatin Announces $10 Million Registered Direct Offering

CRANBURY, N.J. , Oct. 31, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activ...

1 month ago - PRNewsWire

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting

Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J. , Oct. 24, 2022 /PRNewswire/ -- Palatin Te...

1 month ago - PRNewsWire

First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial

Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tole...

1 month ago - PRNewsWire

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results

Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J. , Oct. 13...

1 month ago - PRNewsWire

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin...

2 months ago - PRNewsWire

Palatin to Participate in Ladenburg Thalmann Healthcare Conference

CRANBURY, N.J. , Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the acti...

2 months ago - PRNewsWire

Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter C...

2 months ago - PRNewsWire

Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September...

CRANBURY, N.J. , Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 202...

2 months ago - PRNewsWire

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment o...

Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment ...

3 months ago - PRNewsWire

3 Penny Stocks That Could 10X by 2023

How do you find the best penny stocks? The answer may seem simple, but it's not.

Other symbols: FPAYXELA
3 months ago - InvestorPlace

Palatin Announces Intent to Effect Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company de...

3 months ago - PRNewsWire

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Resul...

3 months ago - PRNewsWire

Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

Gross product sales increased 75% and Prescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J. , July 26, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharm...

4 months ago - PRNewsWire

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® - Gross product sales increased...

6 months ago - PRNewsWire

Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

CRANBURY, N.J. , May 12, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molec...

6 months ago - PRNewsWire

Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

CRANBURY, N.J. , May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the ope...

6 months ago - PRNewsWire

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Posters highlight Palatin's ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J. , May 2, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical...

7 months ago - PRNewsWire

Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin's compound PL9643 for Dry Eye Disease PL9643 Dry Eye Disease Phase 3 study ongo...

7 months ago - PRNewsWire

Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

CRANBURY, N.J. , March 3, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activ...

9 months ago - PRNewsWire

Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

CRANBURY, N.J., Feb. 15, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activi...

9 months ago - PRNewsWire

Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

9 months ago - Zacks Investment Research